SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain ...

ClearPoint Neuro Inc (CLPT) reports a 43% revenue increase and strategic advancements despite rising operational costs.

Q1 2026 Management View “Our company has started 2026 on a strong note by achieving record revenue of $12.1 million for the quarter,” and this was “driven primarily by organic devices growth of 25%,” ...

ClearPoint Neuro’s latest earnings call painted a largely upbeat picture, with record quarterly revenue, expanding margins and meaningful progress on product and regulatory fronts. Management ...

Global Commercial Footprint -- Over 175 active sites are currently using ClearPoint technology, with expectations to surpass ...

ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration FTD is a devastating form of early-onset dementia that ...

ClearPoint Neuro reported total operating expenses of $11.3 million in the quarter. The company ended the period with $12.4 million in cash and cash equivalents. “Our 2025 fiscal year is off to a ...

ClearPoint's stock surged after uniQure announced strong Huntington's data, highlighting the value of its drug delivery platform. CLPT's technology has been validated by the AMT-130 data, positioning ...

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.22 per share a year ago. These ...

SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain ...